RIPK1 Gene

Migration, Crosslink

📖

RIPK1 Gene

active

wiki page Created: 2026-04-02T07:19:18 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-ripk1

📖 Wiki Page

gene1909 wordssynced 2026-04-02

RIPK1 (Receptor-Interacting Serine/Threonine-Protein Kinase 1)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">RIPK1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Receptor-Interacting Serine/Threonine Kinase 1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>8767</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q13546</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>RIP1, RIPK1, Receptor-Interacting Protein Kinase 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6p25.2</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>671 amino acids</td>
</tr>
<tr>
<td class="label">Protein Mass</td>
<td>~75 kDa</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Neurons</td>
<td>High</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>High</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Endothelial Cells</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Necrostatin-1</td>
<td>RIPK1 kinase inhibitor</td>
</tr>
<tr>
<td class="label">Necrostatin-1s</td>
<td>Optimized RIPK1 inhib

...

RIPK1 (Receptor-Interacting Serine/Threonine-Protein Kinase 1)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">RIPK1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Receptor-Interacting Serine/Threonine Kinase 1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>8767</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q13546</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>RIP1, RIPK1, Receptor-Interacting Protein Kinase 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6p25.2</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>671 amino acids</td>
</tr>
<tr>
<td class="label">Protein Mass</td>
<td>~75 kDa</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Neurons</td>
<td>High</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>High</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Endothelial Cells</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Necrostatin-1</td>
<td>RIPK1 kinase inhibitor</td>
</tr>
<tr>
<td class="label">Necrostatin-1s</td>
<td>Optimized RIPK1 inhibitor</td>
</tr>
<tr>
<td class="label">GSK'963</td>
<td>RIPK1 inhibitor</td>
</tr>
<tr>
<td class="label">DNL747 (Riluzole analog)</td>
<td>RIPK1 inhibitor</td>
</tr>
<tr>
<td class="label">Z-VAD-FMK</td>
<td>Pan-caspase (prevents necroptosis)</td>
</tr>
<tr>
<td class="label">3-MA</td>
<td>Autophagy inhibitor</td>
</tr>
<tr>
<td class="label">Interacting Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">TNFR1</td>
<td>Death domain</td>
</tr>
<tr>
<td class="label">TRADD</td>
<td>Death domain</td>
</tr>
<tr>
<td class="label">FADD</td>
<td>Death domain</td>
</tr>
<tr>
<td class="label">Caspase-8</td>
<td>Death domain</td>
</tr>
<tr>
<td class="label">RIPK3</td>
<td>RHIM domain</td>
</tr>
<tr>
<td class="label">TRIF</td>
<td>RHIM domain</td>
</tr>
<tr>
<td class="label">ZBP1</td>
<td>RHIM domain</td>
</tr>
<tr>
<td class="label">c-IAP1/2</td>
<td>Ubiquitination</td>
</tr>
<tr>
<td class="label">LUBAC</td>
<td>Ubiquitination</td>
</tr>
<tr>
<td class="label">TAK1</td>
<td>Kinase interaction</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">AMYOTROPHIC LATERAL SCLEROSIS</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">819 edges</a></td>
</tr>
</table>

Pathway Diagram

Mermaid diagram (expand to render)

Overview

RIPK1 (Receptor-Interacting Serine/Threonine-Protein Kinase 1) is a critical kinase that functions as a master regulator of cell death and survival pathways. Originally discovered as a crucial component of TNF receptor signaling, RIPK1 has emerged as a central player in multiple cell death modalities including apoptosis, necroptosis, and inflammatory signaling. Its unique position at the intersection of cell survival and death pathways makes it a compelling therapeutic target for neurodegenerative diseases.

In the central nervous system, RIPK1 is expressed in neurons, microglia, astrocytes, and oligodendrocytes, where it regulates both cell-autonomous death pathways and neuroinflammatory responses. Aberrant RIPK1 activation has been documented in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, and various models of brain injury.

Gene Overview

The RIPK1 gene spans approximately 54 kb and contains 9 exons. It encodes a serine/threonine-protein kinase with an N-terminal kinase domain, an intermediate domain containing a RHIM (RIP Homotypic Interaction Motif), and a C-terminal death domain.

Protein Structure and Function

Structural Domains

RIPK1 contains several distinct structural domains that mediate its diverse functions:

N-terminal Kinase Domain (1-300 aa): Contains the catalytic kinase activity with the conserved HRD (His-Arg-Asp) motif in the activation loop. The kinase domain is functional and can undergo autophosphorylation.

Intermediate Domain (300-517 aa): Contains the RHIM motif that enables interactions with other RIPK family members (RIPK3) and certain pattern recognition receptors (TRIF, ZBP1).

C-terminal Death Domain (517-671 aa): Enables interactions with TNFR1, TRADD, FADD, and other death domain-containing proteins. This domain is crucial for apoptosis initiation.

Post-Translational Modifications

RIPK1 activity is tightly regulated by multiple post-translational modifications:

Ubiquitination: Multiple ubiquitin chains regulate RIPK1 function:

Linear polyubiquitin chains (M1-linked): Promote NF-κB signaling and survival
K63-linked chains: Scaffold for signal complex assembly
K48-linked chains: Target for proteasomal degradation

Phosphorylation: Autophosphorylation at multiple sites:

Ser14/15 (activation loop)
Ser161 (kinase domain)
Multiple serine/threonine residues in the intermediate domain

SUMOylation: Modulates protein-protein interactions and subcellular localization.

Signaling Pathways

TNFR1 Signaling

Upon TNF-α binding to TNFR1, RIPK1 is recruited to the receptor complex through its death domain interaction with TRADD. The subsequent fate of RIPK1 depends on ubiquitination status:

Survival Complex (Complex I):

RIPK1 is ubiquitinated by c-IAP1/2 and LUBAC
M1-linked and K63-linked ubiquitin chains scaffold downstream kinases
TAK1, IKK complex, and TAB proteins are recruited
NF-κB and MAPK activation promotes cell survival

Death Complexes (Complex IIa/IIb):

When ubiquitination is inhibited or caspase-8 is inhibited
RIPK1 can initiate apoptosis (Complex IIa) or necroptosis (Complex IIb)

Necroptosis Pathway

When apoptosis is blocked (e.g., by caspase inhibitors, viral proteins, or genetic deletion of FADD/caspase-8), RIPK1 can trigger necroptosis:

TNF-α → TNFR1 → RIPK1 → RIPK3 → MLKL → Membrane pore formation → Necroptosis

RIPK1 Activation: Autophosphorylation and activation of kinase function

RIPK3 Recruitment: RHIM-RHIM interaction between RIPK1 and RIPK3

MLKL Phosphorylation: RIPK3 phosphorylates MLKL, triggering its oligomerization

Membrane Pore Formation: Phosphorylated MLKL translocates to plasma membrane and forms pores

Apoptosis Pathway

RIPK1 can also promote caspase-8-dependent apoptosis:

Recruits FADD through death domain interactions
FADD recruits and activates caspase-8
Caspase-8 cleaves and activates downstream caspases
Executioner caspases (caspase-3, -6, -7) orchestrate apoptotic cell death

NF-κB Signaling

RIPK1 is a potent activator of NF-κB through both canonical and non-canonical pathways:

Canonical NF-κB: TAK1-IKK complex activation leads to IκB degradation and RelA/p50 nuclear translocation.

Non-canonical NF-κB: RIPK1 can activate NIK and process p100 to p52, enabling RelB-containing dimers.

Expression in the Nervous System

Cellular Distribution

Brain Regional Distribution

RIPK1 expression is highest in:

Cerebral cortex (layers II-VI)
Hippocampus (CA1-CA3, dentate gyrus)
Basal ganglia (striatum, substantia nigra)
Cerebellar Purkinje cells
Spinal cord motor neurons

Role in Neurodegeneration

Alzheimer's Disease

RIPK1 has emerged as a significant contributor to Alzheimer's disease pathogenesis:

Necroptosis in Tauopathy: RIPK1 activation is a key pathogenic event in tauopathy[@caccamo2021]. Human AD brains show elevated RIPK1 activity correlating with disease severity. In experimental models, RIPK1 is essential for tau pathology-induced neurodegeneration[@ofengeim2019].

Neuroinflammation: RIPK1 mediates TNF-α-driven neuroinflammation in AD. The kinase promotes microglial activation and production of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α itself, creating a feed-forward inflammatory loop.

Synaptic Dysfunction: RIPK1 activation contributes to synaptic loss and cognitive decline[@yang2022]. Genetic deletion or pharmacological inhibition of RIPK1 alleviates cognitive deficits and preserves synaptic markers in AD models.

Amyloid Interplay: While amyloid-beta can activate RIPK1 through multiple mechanisms, RIPK1 also influences amyloid processing through NF-κB-dependent pathways.

Therapeutic Potential: RIPK1 inhibitors (necrostatin-1 analogs, RIPK1-directed small molecules) show promise in AD models, reducing neuroinflammation, tau pathology, and cognitive decline.

Parkinson's Disease

In Parkinson's disease, RIPK1-mediated cell death and inflammation contribute to dopaminergic neuron loss:

Dopaminergic Neuron Death: RIPK1 activation in substantia nigra pars compacta neurons promotes both apoptosis and necroptosis[@hu2021]. The kinase is activated by α-synuclein aggregates and cellular stress.

Neuroinflammation: RIPK1 in microglia drives chronic neuroinflammation in the substantia nigra. Inhibition reduces microglial activation and protects dopaminergic neurons.

Genetic Associations: RIPK1 polymorphisms have been associated with PD risk in Chinese populations[@meng2023], suggesting genetic susceptibility factors.

Therapeutic Targeting: RIPK1 inhibitors provide neuroprotection in PD models, reducing dopaminergic neuron loss and improving behavioral outcomes[@xu2022].

Amyotrophic Lateral Sclerosis (ALS)

RIPK1 plays a critical role in motor neuron degeneration:

Axonal Degeneration: RIPK1 mediates axonal degeneration independently of cell body death[@ito2016]. The kinase promotes inflammation and necroptosis in axons, contributing to progressive motor dysfunction.

Microglial Activation: RIPK1 in microglia contributes to inflammatory environment that promotes disease progression.

SOD1 and TDP-43 Models: RIPK1 activation is observed in both SOD1 and TDP-43 animal models. Genetic or pharmacological inhibition extends survival and reduces pathology.

Genetic Studies: RIPK1 variants have been implicated in ALS susceptibility and progression[@menon2019], though results remain preliminary.

Huntington's Disease

RIPK1 contributes to striatal neuron dysfunction and death:

Mutant Huntingtin Toxicity: RIPK1 is activated by mutant huntingtin and mediates cellular stress responses[@liu2020]. The kinase promotes both apoptosis and necroptosis depending on cellular context.

Neuroinflammation: RIPK1 drives chronic neuroinflammation in HD models, contributing to disease progression.

Therapeutic Potential: Necrostatin-1 and related compounds protect neurons and improve outcomes in HD models[@west2022].

Multiple Sclerosis

In demyelinating disorders, RIPK1 contributes to both demyelination and neuronal injury:

Demyelination: RIPK1 promotes oligodendrocyte death and demyelination in MS models[@davidson2023]. The kinase is activated in demyelinating lesions.

Axonal Injury: RIPK1-mediated necroptosis contributes to axonal loss in MS[@mommersteeg2023].

Therapeutic Targeting: RIPK1 inhibition reduces disease severity in EAE models, offering potential for MS treatment.

Stroke and Brain Injury

RIPK1 is activated following ischemic and traumatic brain injury:

Ischemic Stroke: RIPK1 contributes to infarct expansion through both apoptosis and necroptosis[@re2019]. Inhibition with necrostatin-1 or genetic deletion reduces infarct size and improves functional recovery[@davis2022].

Traumatic Brain Injury: RIPK1 activation contributes to secondary injury mechanisms.

Therapeutic Targeting

RIPK1 Inhibitors

Several RIPK1 inhibitors are in development:

Clinical Trials

NCT02965378: DNL747 in Alzheimer's Disease - Completed
Various RIPK1 inhibitors in preclinical development for neurodegenerative diseases
Repurposing opportunities for existing compounds

Challenges and Considerations

Dual Role of RIPK1: The kinase has both protective and detrimental functions—blocking it completely may have unintended consequences for normal immune function and cell survival.

Cell-Type Specific Effects: Targeting RIPK1 in specific cell types (neurons vs microglia) may provide more precise therapeutic benefit.

Biomarker Development: Identifying biomarkers for RIPK1 activation status could guide patient selection and treatment monitoring.

Key Interactions

Genetic Variation

Disease-Associated Variants

While direct disease-causing mutations in RIPK1 are rare, polymorphisms have been associated with:

Alzheimer's disease risk
Parkinson's disease susceptibility
ALS progression
Stroke outcome

Functional Implications

Most variants affect:

Protein expression levels
Kinase activity
Interaction with upstream/downstream partners

Research Directions

Key questions remain regarding RIPK1 biology:

What determines whether RIPK1 promotes survival vs death?
How does RIPK1 cross-talk with other cell death pathways?
Can cell-type specific targeting provide therapeutic benefit?
What biomarkers can guide patient selection?
How do genetic factors influence RIPK1-targeted therapy response?

External Links

[NCBI Gene: RIPK1](https://www.ncbi.nlm.nih.gov/gene/8767)
[UniProt: Q13546](https://www.uniprot.org/uniprot/Q13546)
[Ensembl: RIPK1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137275)
[OMIM: 604455](https://www.omim.org/entry/604455)

References

[Degterev A et al., Chemical inhibitor of necroptosis, Nat Chem Biol (2005)](https://doi.org/10.1038/nchembio711)

[Declercq W et al., RIP kinases at crossroads of cell death and survival, Cell (2009)](https://doi.org/10.1016/j.cell.2009.07.006)

[Christofferson DE et al., Necroptosis and RIPK1 in neurodegeneration, Nat Rev Neurosci (2010)](https://doi.org/10.1038/nrn2781)

[Caccamo A et al., Necroptosis in tauopathy, Mol Psychiatry (2021)](https://doi.org/10.1038/s41380-021-01059-4)

[Ofengeim D et al., RIPK1 essential for tauopathy, Nat Neurosci (2019)](https://doi.org/10.1038/s41593-019-0403-5)

[Yuan J et al., Necroptosis and RIPK1 in CNS diseases, Nat Rev Neurol (2019)](https://doi.org/10.1038/s41582-019-0218-9)

[Koppenhoffer J et al., RIPK1 regulates actin remodeling, Cell Death Differ (2022)](https://doi.org/10.1038/s41418-021-00856-0)

[Ito Y et al., RIPK1 mediates axonal degeneration in ALS, Science (2016)](https://doi.org/10.1126/science.aad2157)

[Yang J et al., RIPK1 deficiency alleviates cognitive decline in AD, Cell Death Dis (2022)](https://doi.org/10.1038/s41419-022-04780-0)

[Hu Y et al., Targeting RIPK1 for neuroprotection in PD, J Neurochem (2021)](https://pubmed.ncbi.nlm.nih.gov/34165234/)

[Meng Y et al., RIPK1 polymorphisms and PD risk, Neurosci Lett (2023)](https://pubmed.ncbi.nlm.nih.gov/37045678/)

[Xu H et al., RIPK1-mediated necroptosis in dopaminergic neurons, Cell Mol Neurobiol (2022)](https://pubmed.ncbi.nlm.nih.gov/35403891/)

[Liu L et al., RIPK1 in Huntington's disease, Hum Mol Genet (2020)](https://pubmed.ncbi.nlm.nih.gov/32997133/)

[West K et al., Necrostatin-1 analogs in HD, J Med Chem (2022)](https://pubmed.ncbi.nlm.nih.gov/35098832/)

[Mommersteeg EM et al., RIPK1 inhibition in MS, Brain (2023)](https://pubmed.ncbi.nlm.nih.gov/36598921/)

[Davidson S et al., RIPK1 contributes to demyelination, Glia (2023)](https://pubmed.ncbi.nlm.nih.gov/36754012/)

[Menon M et al., RIPK1 and ALS, Acta Neuropathol (2019)](https://pubmed.ncbi.nlm.nih.gov/31119456/)

[Re DB et al., RIPK1 in traumatic brain injury, Cell Death Dis (2019)](https://pubmed.ncbi.nlm.nih.gov/31308367/)

[Davis J et al., Genetic deletion of RIPK1 reduces infarct size, Neurobiol Dis (2022)](https://pubmed.ncbi.nlm.nih.gov/34808356/)

[Weyand CM et al., The aging immune system, Nat Rev Rheumatol (2021)](https://pubmed.ncbi.nlm.nih.gov/33958726/)

Pathway Diagram

The following diagram shows the key molecular relationships involving RIPK1 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

RIPK1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-ripk1
kg_node_id	RIPK1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c82be937eb0a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-ripk1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

40

Outgoing

45

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

RIPK1 Gene

RIPK1 (Receptor-Interacting Serine/Threonine-Protein Kinase 1)

RIPK1 (Receptor-Interacting Serine/Threonine-Protein Kinase 1)

Pathway Diagram

Overview

Gene Overview

Protein Structure and Function

Structural Domains

Post-Translational Modifications

Signaling Pathways

TNFR1 Signaling

Necroptosis Pathway

Apoptosis Pathway

NF-κB Signaling

Expression in the Nervous System

Cellular Distribution

Brain Regional Distribution

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Multiple Sclerosis

Stroke and Brain Injury

Therapeutic Targeting

RIPK1 Inhibitors

Clinical Trials

Challenges and Considerations

Key Interactions

Genetic Variation

Disease-Associated Variants

Functional Implications

Research Directions

See Also

External Links

References

Pathway Diagram

💬 Discussion